Maxim analyst Naz Rahman raised the firm’s price target on Clene (CLNN) to $30 from $20 and keeps a Buy rating on the shares after the company and its wholly owned subsidiary Clene Nanomedicine announced completion of the FDA-recommended biomarker analyses for CNM-Au8 in people living with ALS. The results demonstrate statistically significant reductions in both neurofilament light, NfL, and glial fibrillary acidic protein, GFAP, which “clears way” for an NDA filing, the analyst says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Clene’s CNM-Au8 Shows Promise in ALS Treatment, Projecting Significant Stock Upside
- Clene Updates on CNM-Au8® ALS Program
- Clene Announces Positive Biomarker Results for CNM-Au8
- Clene announces significant reductions in NfL, GFAP when treated with CNM-Au8
- Clene Inc.: Promising Future with CNM-Au8 Advancements and Strategic Financial Management